Clinical Trials
12 trialsNCT03164993 2024-10-15
ALICE
Oslo University Hospital
Phase 2 Completed
NCT03409198 2024-10-15
ICON
Oslo University Hospital
Phase 2 Completed
NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT00913835 2019-09-26
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00563953 2017-10-12
CAPRICE
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT00523380 2017-03-01
Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer
Novo Nordisk A/S
Phase 2 Completed
NCT02081495 2016-11-11
A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT01815294 2015-12-04
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT00770536 2015-09-29
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
Phase 1 Completed
NCT00722592 2015-01-07
PRECEDENT
Endocyte
Phase 2 Completed
NCT01455532 2014-10-22
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
Sanofi
Phase 1 Completed
NCT00183742 2014-05-22
Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
University of Southern California
Phase 1 Completed